Quick answer
Immunitybio, Inc. (IBRX) reported revenue of $113.3M and net loss of $351.4M for the fiscal year ended 2025-12-31, up 668.3% from $14.7M the year before, per its 10-K filed with the SEC on 2026-02-23.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $113.3M | -$351.4M | — |
| 2024 (FY ending 2024-12-31) | $14.7M | -$413.6M | — |
| 2023 (FY ending 2023-12-31) | $0.6M | -$583.2M | — |
| 2022 (FY ending 2022-12-31) | $0.2M | -$416.6M | — |
| 2021 (FY ending 2021-12-31) | $0.9M | -$346.8M | — |
| 2020 (FY ending 2020-12-31) | $0.6M | -$221.9M | — |
| 2019 (FY ending 2019-12-31) | $2.2M | -$157.8M | — |
| 2018 (FY ending 2018-12-31) | $0.0M | -$96.2M | — |
| 2017 (FY ending 2017-12-31) | $0.0M | -$96.4M | — |
| 2016 (FY ending 2016-12-31) | $0.0M | -$120.8M | — |
Related
- HUT revenue, net income and debt history (Hut 8 Corp.)
- HWM revenue, net income and debt history (Howmet Aerospace Inc.)
- IBM revenue, net income and debt history (International Business Machines Corp)
- ICE revenue, net income and debt history (Intercontinental Exchange, Inc.)
- IDA revenue, net income and debt history (Idacorp Inc)
- IDCC revenue, net income and debt history (Interdigital, Inc.)
- IDXX revenue, net income and debt history (Idexx Laboratories Inc /De)
- IESC revenue, net income and debt history (IES Holdings, Inc.)
Last updated 2026-10-16. Data only, not financial or tax advice.